Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.49 |
| ▸ | MTTP | P55157 | 7/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13839839 | 0.93 | MTTP (0.55) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13839802 | 0.92 | MTTP (0.57) | MTTP | |
| SCHEMBL13839832 | 0.86 | GAA (0.48) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13839831 | 0.86 | GAA (0.53) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13839824 | 0.86 | NPY2R (0.56) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13839811 | 0.85 | MTTP (0.66) | MTTP | |
| SCHEMBL13839834 | 0.85 | GAA (0.47) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13839797 | 0.80 | MTTP (0.62) | MTTP | |
| SCHEMBL13839789 | 0.79 | MTTP (0.51) | MTTP | |
| SCHEMBL13839827 | 0.79 | MTTP (0.59) | NPY2RMTTPCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538124-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-26 | — | — | US | disclosed |
| US-7538124-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-26 | — | — | US | disclosed |
| US-20080275087-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-11-06 | — | — | US | disclosed |
| US-20080275087-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-11-06 | — | — | US | disclosed |
| US-7405307-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-29 | — | — | US | disclosed |
| US-7405307-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-29 | — | — | US | disclosed |
| US-20080009522-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-01-10 | — | — | US | disclosed |
| US-20080009522-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-01-10 | — | — | US | disclosed |
| US-7304167-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7304167-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7244848-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
| US-7244848-B2 | Biphenylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009522-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, FABP4 | NPY2R 1732/4885MTTP 22/4885CHRNB2 4621/4885 |
| US-20080275087-A1 | BIPHENYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, FABP4 | NPY2R 1732/4885MTTP 22/4885CHRNB2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.